# Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

> **NCT03179605** · PHASE2 · TERMINATED · sponsor: **Primus Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** DFD06

## Key facts

- **NCT ID:** NCT03179605
- **Lead sponsor:** Primus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-02
- **Primary completion:** 2019-06-03
- **Final completion:** 2020-06-03
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Difficulty in enrollment
- **Last updated:** 2024-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179605, "Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03179605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*